Vitiligo Clinical Trial
Official title:
Structural Evaluation of Human Melanocytes After the Use of Autologous Platelet-rich Plasma (PRP) Versus Fractional Carbon Dioxide Laser (Fr:CO2 Laser) in Treatment of Vitiligo: (A Histological, Immunohistochemical and Molecular Study )
Vitiligo is considered the most common chronic depigmentation disorder that affects around
0.5 -2% of the world population . In Africa , its prevelance is around 0.4% and 1.22 % in
Assiut .
Treatment of vitiligo includes medical topical and systemic immune -suppressants
,phototherapy and surgical modalities .Despite the numerous treatment options , the treatment
of choice is still controversial as the response is variable , unsatisfactory ,and requires a
prolonged course. Therefore, new therapeutic approaches are required .
Platelet -rich plasma (PRP) is a treatment modality which has been used over the last several
years in various medical and surgical fields . It is composed of high concentration of
platelets , several growth factors and plasma proteins such as fibrin, fironectin
,vitronectin .This is hypothesized to stimulate keratinocytes and fibroblasts proliferation .
Another treatment modality is the fractional CO2 (Fr: CO2) laser .There are theories that
fractional CO2 laser causes release of various types of cytokines and growth factors that can
stimulate migration of melanocytes and act as mitogens for melanogenesis .
Melanogenesis is a complex process with involvement of multiple signaling pathways.
Therefore, there have been extensive efforts to reveal the molecular mechanisms that control
melanogenesis as the main step for treating hypopigmentary skin disorders .
There is yet very limited histopathological and molecular information about how the signaling
networks are involved in the initiation , progression and also treatment of vitiligo disease.
Vitiligo is considered the most common chronic depigmentation disorder that affects around
0.5 -2% of the world population .In Africa , its prevelance is around 0.4% and 1.22 % in
Assiut .
Vitiligo may appear at any age and affect both sexes. It is a cosmetically disfiguring
disorder characterized by formation of depigmented patches of skin and /or mucosa.It has a
psychological devastating effect which could lead to low self-steam and poor body image .
Vitiligo disease has three types according to the distribution of lesions ; segmental,
non-segmental and mixed vitiligo .It could be classified as progressing or stable according
to the activity of the disease .
Vitiligo pathogenesis includes many theories (the combination theory). The important theories
include: autoimmune destruction of melanocytes, genetic predisposition , altered redox status
and free radical mediated melanocyte damage , impaired melanocyte adhesion or
melanocytorrhagy and heightened sympathetic response and catecholamines/ neurotransmitter
mediated melanocyte damage .
The treatment of vitiligo depends upon the clinical diagnosis and usually includes two
strategies.
The first strategy aims to provide stability by arresting the progression of the active
disease and therefore limiting the depigmented areas. The second strategy is repigmentation
of the depigmented areas Treatment of vitiligo includes medical topical and systemic immune
-suppressants ,phototherapy and surgical modalities .
First line of treatment includes topical corticosteroids ,calcineurin inhibitors and
phototherapy . While the second line of treatment includes systemic corticosteroids , topical
calcipotriol and excimer laser .Surgical methods include skin /single-hair grafting ,
autologous cultured melanocyte or epidermal suspension transplantations and immunomodulators
.
Despite the numerous treatment options , the treatment of choice is still controversial as
the response is variable , unsatisfactory ,and requires a prolonged course . High proportion
of vitiligo patients are resistant to the treatment. Therefore, new therapeutic approaches
are required .
Platelet -rich plasma (PRP) is a treatment modality which has been used over the last several
years in various medical and surgical fields .It is a simple and cheap new break thorough in
soft tissue healing which has attracted the attention of dermatologists in the skin
rejuvenation field .
PRP is composed of high concentration of platelets (seven times the normal blood level ),
several growth factors and plasma proteins such as fibrin, fironectin ,vitronectin . Growth
factors are known to regulate many processes such as cell migration , proliferation and
differentiation .This is hypothesized to stimulate keratinocytes and fibroblasts
proliferation .
Another treatment modality is the fractional CO2 (Fr: CO2) laser which represents a new
modality for skin rejuvenation based on the theory of fractional photothermolysis . It has
been used in treating facial photo-aging and scars . There are theories that fractional CO2
laser causes release of various types of cytokines and growth factors that can stimulate
migration of melanocytes and act as mitogens for melanogenesis .
Melanogenesis is a complex process with involvement of multiple signaling pathways.
Therefore, there have been extensive efforts to reveal the molecular mechanisms that control
melanogenesis as the main step for treating hyperpigmentary skin disorders .
Molecular signaling pathways include p38 Mitogen-activated protein kinase (MAPK) , c-Jun
N-terminal kinase /stress -activated protein kinase (JNK/SAPK) and extracellular
signal-regulated kinase (ERK). These pathways are important in regulating cell proliferation
,differentiation and apoptosis of melanocytes .
Another important signaling pathway is protein kinase B ( Akt )which is involved in the
differentiation of the keratinocytes. Activation of the Akt pathway triggers the
differentiation process and is sustained until reaching the last stage of keratinocytes
differentiation.
There is yet very limited histopathological and molecular information about how these
signaling networks are involved in the initiation , progression and also treatment of
vitiligo disease.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |